ExodusPoint Capital Management’s Pacific Biosciences PACB Stock Holding History

ExodusPoint Capital Management’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-25,573	Closed	-$32K	–	1891
2025 Q2	$32K	Buy	+25,573	New	+$29.5K	﹤0.01%	1377
2023 Q1	–	Sell	-12,413	Closed	-$102K	–	2039
2022 Q4	$102K	Buy	+12,413	New	+$107K	﹤0.01%	1515
2022 Q2	–	Sell	-30,141	Closed	-$274K	–	2310
2022 Q1	$274K	Buy	30,141 +20,031	+198%	+$231K	﹤0.01%	1795
2021 Q4	$207K	Buy	+10,110	New	+$244K	﹤0.01%	1815
2021 Q1	–	Sell	-106,454	Closed	-$2.76M	–	2476
2020 Q4	$2.76M	Buy	+106,454	New	+$1.81M	0.03%	422
2019 Q4	–	Sell	-10,325	Closed	-$53K	–	1795
2019 Q3	$53K	Buy	+10,325	New	+$57.7K	﹤0.01%	1277

Other funds holding PACB

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EDRH

Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return

ExodusPoint Capital Management's PACB Position: Q3 2025 in Review

ExodusPoint Capital Management sold out of Pacific Biosciences (PACB) in Q3 2025, closing a stake of 25,573 shares — an estimated $32K sold.

ExodusPoint Capital Management first reported a position in PACB in Q3 2019 and held it in 6 quarters. The position peaked at $2.76M in Q4 2020. 208 funds tracked by Wall St. Rank hold PACB as of Q3 2025.

ExodusPoint Capital Management reported no remaining Pacific Biosciences position as of Q3 2025 after selling out during the quarter.
ExodusPoint Capital Management sold 25,573 Pacific Biosciences shares in Q3 2025, an estimated $32K.
ExodusPoint Capital Management first reported a position in Pacific Biosciences in Q3 2019 and held it in 6 quarters.
ExodusPoint Capital Management's Pacific Biosciences position peaked at $2.76M in Q4 2020.
208 funds tracked by Wall St. Rank held Pacific Biosciences as of Q3 2025.

Based on ExodusPoint Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.